

Annex to:

EFSA CONTAM Panel (EFSA Panel on Contaminants in the Food Chain), Schrenk D, Bignami M, Bodin L, Chipman JK, del Mazo J, Grasl-Kraupp B, Hogstrand C, Hoogenboom LR, Leblanc J-C, Nebbia CS, Nielsen E, Ntzani E, Petersen A, Sand S, Schwerdtle T, Wallace H, Benford D, Fürst P, Rose M, Ioannidou D, Nikolić M, Ramos Bordajandi L and Vleminckx C, 2021. Scientific Opinion – Update of the risk assessment of hexabromocyclododecanes (HBCDDs) in food. EFSA Journal 2021;19(3):6421, <https://doi.org/10.2903/j.efsa.2021.6421>

© 2021 European Food Safety Authority. EFSA Journal published by John Wiley and Sons Ltd on behalf of European Food Safety Authority.

ANNEX A - Protocol for the human risk assessments related to the presence of brominated flame retardants (BFRs) in food

The current protocol or strategy reports on the problem formulation and approach selected by the Panel on Contaminants in the Food Chain (CONTAM Panel) to update the previous risk assessments of brominated flame retardants (BFRs) in food. The protocol is in accordance with the draft framework for protocol development for EFSA's scientific assessments (EFSA, 2020). This framework foresees that the extent of planning in the protocol (i.e. the degree of detail provided in the protocol for the methods that will be applied in the assessment) can be tailored to accommodate the characteristics of the mandate. Considering the timelines and the available resources, the CONTAM Panel applied a low level of planning.

A.1. Problem formulation

Objectives of the risk assessments

The objectives of the risk assessments aim at assessing the risk for adverse effects in humans associated with the dietary exposure to BFRs in food.

The BFRs to be considered are hexabromocyclododecanes (HBCDDs), polybrominated diphenyl ethers (PBDEs), tetrabromobisphenol A (TBBPA) and its derivatives, brominated phenols and their derivatives, and emerging and novel BFRs¹. The CONTAM Panel published a series of Opinions on the risk assessments of these BFRs in food between 2011 and 2012 (EFSA CONTAM Panel, 2011a,b,c, 2012a,b), and these will be the starting point for the present updates of the risk assessments.

The similarities in chemical properties and effects seen in the previous EFSA assessments for the different BFR families warrant the consideration of a mixture approach. The CONTAM Panel will evaluate the appropriateness of applying a mixture approach in an additional Opinion once the risk assessments for each BFR family has been updated. It will be based on the EFSA Guidance on harmonised methodologies for human health, animal health and ecological risk assessment of combined exposure to multiple chemicals (EFSA Scientific Committee, 2019).

Target populations

The target population of the human risk assessment is the European population, including specific vulnerable groups (fetus and breastfed infants) and groups with high exposure due to dietary preferences, e.g. high and frequent fish consumers.

BFRs of concern and route of exposure

The risk assessments will focus on the dietary exposure to BFRs as in Table A.1.

¹ As defined in EFSA (2012c).

Table A.1. BFRs to be considered

| | |
|--|--|
| HBCDDs | Studies with single stereoisomers (α -, β - and γ -HBCDD) Studies with mixtures of the stereoisomers (α -, β - and γ -HBCDD) Studies with HBCDD technical mixture Studies with mixture of different categories of BFRs, including HBCDDs |
| PBDEs | Studies with single congeners Studies with mixtures of single congeners Studies with PBDE technical mixtures Studies with mixture of different categories of BFRs, including PBDEs |
| TBBPA and its derivatives | Studies with TBBPA or any of its derivatives Studies with mixtures of TBBPA and any of its derivatives Studies with TBBPA technical mixtures Studies with mixture of different categories of BFRs, including TBBPA and/or any of its derivatives |
| Brominated phenols and their derivatives | Studies with single brominated phenols or any of their derivatives Studies with mixtures of brominated phenols and any of its derivatives Studies with technical mixtures of brominated phenols Studies with mixture of different categories of BFRs, including one or more of the brominated phenols and their derivatives |
| Emerging and novel BFRs | Studies with any of the emerging and novel BFRs Studies with mixtures of any of the emerging and novel BFRs, Studies with technical mixtures of any of the emerging and novel BFRs, Studies with mixture of different categories of BFRs, including one or more of the emerging and novel BFRs |

Potential influence of other flame retardants and associated contaminants and by-products (e.g. brominated dioxins and furans) on the outcome will be addressed in the uncertainty analysis.

It will be considered whether brominated Organo Phosphate (OP) flame retardants evaluated in the previous Opinion on emerging and novel BFRs, i.e. tris(2,3-dibromopropyl) phosphate (TDBPP) and tris(tribromoneopentyl) phosphate (TTBNPP), are to be tackled within the current updates of the risk assessments or in a separated assessment together with, e.g. other OP halogenated flame retardants.

Consideration will be given to potential non-dietary sources of exposure, e.g. dust, to indicate the relative importance of the diet to the overall BFR exposure.

Adverse effects and endpoints

The human risk assessment will address the adverse effects associated with the exposure to BFRs as identified in the hazard identification step.

Identification of the risk assessment sub-questions

A series of sub-questions under each risk assessment pillar (i.e. hazard identification, hazard characterisation and exposure assessment) will be answered and combined for performing the risk assessment. The sub-question identified are reported in Table A.2.

Table A.2. Sub-questions to be answered for the risk assessment

| Risk assessment step | No | Sub-questions |
|-------------------------|----|---|
| Hazard identification | 1 | What adverse outcomes are caused by exposure to BFRs ^(a) in experimental animals? |
| Hazard identification | 2 | What adverse outcomes are associated with exposure to BFRs in humans? |
| Hazard identification | 3 | Are the different classes of BFRs genotoxic? |
| Hazard characterisation | 4 | What is the absorption, distribution, metabolism and excretion (ADME) of BFRs in experimental animal species/strains? |
| Hazard characterisation | 5 | What is the ADME of BFRs in humans? |
| Hazard characterisation | 6 | What is the difference in ADME of BFRs between humans and experimental animals? |
| Hazard characterisation | 7 | What is the dose-response relationship between BFRs and relevant endpoints in experimental animals? |
| Hazard characterisation | 8 | What is the dose-response relationship between BFRs and relevant endpoints in humans? |
| Hazard characterisation | 9 | What is the mode of action that can explain the observed adverse effects by BFRs? |
| Exposure assessment | 10 | What are the levels of BFRs in food in Europe? |
| Exposure assessment | 11 | What is the effect of processing on the levels of BFRs in food? |
| Exposure assessment | 12 | What are the consumption levels of foods among the European population? |
| Exposure assessment | 13 | What is the estimate of exposure to BFRs from the diet in the European population? |
| Exposure assessment | 14 | What are the concentrations of BFRs in, e.g. blood, breast milk, adipose tissue, placenta in the European population? |
| Exposure assessment | 15 | What is the contribution of non-dietary exposure to the total exposure? |

ADME: absorption, distribution, metabolism and elimination.

(a): The BFRs to be considered are hexabromocyclododecanes (HBCDDs), polybrominated diphenyl ethers (PBDEs), tetrabromobisphenol A (TBBPA) and its derivatives, brominated phenols and their derivatives, and emerging and novel BFRs (EFSA CONTAM Panel, 2011a,b,c, 2012a,b).

Studies on both humans and experimental animals will be used for the hazard identification and characterisation. The potential association between the target compound(s) and the endpoints of interest for the human risk assessment will be evaluated. It will include an assessment of the dose-response relationship and an evaluation of possible uncertainties, for example those derived from consideration of the toxicokinetic and toxicodynamic properties of the target compounds and from considerations of inter-species variability. As a next step, the human dietary exposure to the target compounds will be estimated. The final step will be the comparison of the exposure estimates to a health-based guidance value (HBGVs, e.g. a tolerable intake) or calculate the margin of exposure (MOE).

A.2. Method for answering the sub-questions

The sub-questions formulated in Table A.1 will be answered by a comprehensive narrative approach. A literature search will be performed to identify primary research studies as well as reviews and meta-analysis relevant to the sub-questions formulated. In addition, the bibliography of the key full text papers will be checked for further potential relevant studies. This technique is known as snowballing.

The expertise of the working group will be used in deciding whether to pursue these further to complement the evidence collection.

To inform the sub-question related to the hazard identification and characterisation (**sub-questions 1 to 9**), all studies reporting effects in humans (i.e. epidemiological studies), and all *in vivo* studies in experimental animals that reported effects after exposure to the BFRs will be considered. The eligibility criteria related to the report characteristic are listed in Table A.3 (and apply to all sub-questions). The eligibility criteria related to study characteristics are listed in Tables A.4, A.5 and A.6 for studies in humans, in experimental animals and toxicokinetic studies.

The details of the studies will be reported in tables and discussed in the corresponding section of the Opinion. The experimental animal studies will be reported by: (i) animal species, (ii) endpoint, (iii) target compound(s) tested and (iii) study duration. The human epidemiological studies will be reported by: (i) endpoint, (ii) target compound(s) analysed and (iii) study design.

The selection of the scientific studies for inclusion or exclusion will be done by the relevant domain experts from the CONTAM WG on BFRs and CONTAM Panel. It will be based on consideration of the extent to which the study is relevant to the assessment, and on general study quality considerations (e.g. sufficient details on the methodology, performance and outcome of the study, on dosing, substance studied and route of administration and on statistical description of the results), irrespective of the results. Major limitations in the information used will be documented in the scientific Opinions.

Table A.3. Eligibility criteria related to report characteristics (all sub-questions)

| | | |
|-------------------------|-----|--|
| Language | In | English ^(a) |
| Time | In | HBDDDs: From 2010 onwards PBDEs: from 2010 onwards TBBPA and its derivatives: from 2010 onwards Brominated phenols and their derivatives: from 2011 onwards Emerging and Novel BFRs: from 2011 onwards |
| Publication type | In | Peer-reviewed primary research studies (i.e. studies generating new data), systematic reviews, reviews, meta-analyses, extended abstracts, conference proceedings, PhD Theses |
| | Out | Editorials, letters to the editor |

(a): Studies in languages other than English might also be cited if considered relevant by the experts from the CONTAM WG on BFRs or CONTAM Panel.

Table A.4. Eligibility criteria for the selection of human epidemiological studies

| Sub-questions 1 and 7 | | |
|-------------------------------|-----|---|
| Study design | In | Cross-sectional studies Cohort studies Case-control studies (retrospective and nested) Case series/Case reports Clinical trials |
| | Out | Animal studies <i>In vitro</i> studies |
| Study characteristics: | In | Any study duration Any number of subjects |
| | Out | / |
| Population | In | All populations groups, all ages, males and females Study location: all countries |
| | Out | / |
| Exposure/ intervention | In | All routes of exposure (dietary, dermal, inhalation, transplacental exposure). <u>Exposure:</u> - Studies in which levels of the BFRs have been measured in human tissues - Studies in which the dietary exposure to the BFRs has been estimated |
| | Out | / |
| | In | All endpoints, including hormone levels |

| | | |
|-------------------------------------|-----|---|
| Specific outcome of interest | Out | / |
|-------------------------------------|-----|---|

Table A.5. Eligibility criteria for the selection of studies in experimental animals and *in vitro* studies

| Sub-question 2, 3, 8 and 9 | | |
|-------------------------------------|-----|--|
| Study design | In | Experimental animal studies (rats, mice, monkeys, guinea pig, mini pigs, rabbit, hamster, dog, cat, mink) <i>In vitro</i> studies |
| | Out | Human studies |
| Study characteristics: | In | Any study duration Any number of animals Any human culture cells/models |
| | Out | / |
| Population | In | Any age, males and females |
| | Out | / |
| Exposure/ intervention | In | <u>Route of administration:</u> Oral (feeding, gavage studies), <i>s.c.</i> , <i>i.p.</i> , <i>i.m.</i> <u>Compounds:</u> as specified in Section A.1 under 'BFRs of concern and route of exposure' OR Estimated exposure validated <u>Number of doses:</u> single or repeated administration <u>Dose groups:</u> ≥ 1 dose groups + control group |
| | Out | Inhalation, dermal application Studies on other BFR |
| Specific outcome of interest | In | All endpoints |
| | Out | / |

Table A.6. Eligibility criteria for the studies on toxicokinetics

| Sub-questions 4, 5 and 6 | | |
|-------------------------------------|-----|---|
| Study design / Test system | In | <i>In vivo</i> studies in humans <i>In vivo</i> studies in experimental animals <i>In vitro</i> studies in human culture cells/models |
| | Out | / |
| Exposure/ intervention | In | Any of the classes of BFRs under evaluation, individually or as mixtures |
| | Out | / |
| Specific outcome of interest | In | Any outcome related to the absorption, distribution, metabolism and elimination of the target compounds |

Information about previous risk assessments by international bodies, chemistry, analytical methods, current EU legislation, previously reported occurrence data in food and exposure assessments (including time trends), as reported in the literature, will be gathered and summarised in a narrative way (supported by tables, if relevant) based on expert knowledge and judgement.

The general principles of the risk assessment process for chemicals in food as described by WHO/IPCS (2009) will be applied, which include hazard identification and characterisation, exposure assessment and risk characterisation. In addition, the following EFSA guidance documents pertaining to risk assessment will be followed for the development of the risk assessment:

- Guidance of the Scientific Committee on a request from EFSA related to uncertainties in Dietary Exposure Assessment (EFSA Scientific Committee, 2007),

- Guidance of the Scientific Committee on transparency in the scientific aspects of risk assessments carried out by EFSA. Part 2: General principles (EFSA Scientific Committee, 2009),
- Management of left-censored data in dietary exposure assessment of chemical substances (EFSA, 2010a),
- Guidance of EFSA on the use of the EFSA Comprehensive European Food Consumption Database in exposure assessment (EFSA, 2011a),
- Overview of the procedures currently used at EFSA for the assessment of dietary exposure to different chemical substances (EFSA, 2011b),
- Scientific Opinion on genotoxicity testing strategies applicable to food and feed safety assessment (EFSA Scientific Committee, 2011)
- Guidance on selected default values to be used by the EFSA Scientific Committee, Scientific Panels and Units in the absence of actual measured data (EFSA Scientific Committee, 2012a),
- Scientific Opinion on Risk Assessment terminology (EFSA Scientific Committee, 2012b).
- Update: Guidance on the use of the benchmark dose approach in risk assessment (EFSA Scientific Committee, 2017a)
- Guidance on harmonised methodologies for human health, animal health and ecological risk assessment of combined exposure to multiple chemicals (EFSA Scientific Committee, 2019).
- Scientific Opinion on the guidance on the use of the weight of evidence approach in scientific assessments (EFSA Scientific Committee, 2017b).
- Guidance on the assessment of the biological relevance of data in scientific assessments (EFSA Scientific Committee, 2017c).
- Guidance on Uncertainty Analysis in Scientific Assessments (EFSA Scientific Committee, 2018).
- Guidance on Communication of Uncertainty in Scientific Assessments (EFSA, 2019).

Literature searches

The literature searches to inform the risk assessments on BFRs will be performed searching the following bibliographic databases or scientific citation research platforms:

1. PubMed
2. Web of Science™, encompassing the following databases:
 - Web of Science™ Core Collection
 - BIOSIS Citation IndexSM
 - CABI: CAB Abstracts[®]
 - Current Contents Connect[®]
 - Data Citation IndexSM
 - FSTA[®] – the food science resource
 - MEDLINE[®]
 - SciELO Citation Index
 - Zoological Record[®]

The literature searches for studies relevant to HBCDDs and emerging and novel BFRs will be performed by EFSA staff, while those on the oral toxicity and mode of action of PBDEs, TBBPA and brominated phenols and their derivatives will be outsourced to an external contractor.

The output from the searched databases, i.e. the bibliographic references including relevant information, e.g. title, authors, abstract, will be exported into separate Endnote files, allowing a count of the individual hits per database. Files will then be combined, and duplicate records will be removed. The selection process will be performed either in a web-based systematic review software, e.g. with DistillerSR[®] (Evidence Partners, Ottawa, Canada) or using xls or word files.

In addition, grey literature was also identified by a dedicated search in the Organohalogen Compounds database (extended abstracts from DIOXIN conferences) and in the BFR conference abstracts available from its website.

Integration of the lines of evidence for hazard identification and method to perform hazard characterisation

The final critical endpoints will be identified by integrating evidence from both human and experimental animal lines of evidence considering the respective level of confidence. A dose-response assessment

will be performed on relevant adverse effects for the identification of reference points, e.g. a no-observed-adverse-effect level (NOAEL) or a benchmark dose (BMD) and its lower confidence limit (BMDL) for a particular incidence of effect. The lowest reference point will be considered for the possible derivation of an HBGV or to calculate the MOE.

Data on the toxicokinetics (ADME and toxicokinetic modelling) will support the extrapolation of results from experimental animal studies and human studies to the general population. This information is also important to determine which uncertainty factors related to inter-species difference and inter-individual variability need to be taken into account when establishing an HBGV or an MOE.

Information on mode of action will also support this step, as mode of action studies can establish the key events and their relationships required for the various adverse outcomes as a result of BFR exposure.

A.3. Method to address the exposure assessment sub-questions

To address **sub-question 10** on the levels of BFRs in food in European countries, a structured approach will be followed to collect and evaluate the evidence. The available occurrence data on BFRs in food will be extracted from the EFSA database by the EFSA Evidence Management Unit. Occurrence data are collected through the continuous annual call for data issued by EFSA requesting data on a list of prioritised chemical contaminants². National food authorities and also research institutions, academia, food business operators and other stakeholders are invited to submit data occurrence by the 1st of October of each year. The data submission to EFSA must follow the requirements of the EFSA Guidance on Standard Sample Description for Food and Feed (EFSA, 2010b); occurrence data will be managed following the EFSA standard operational procedures (SOPs) on 'Data collection and validation' and on 'Data analysis and reporting'.

For these risk assessments all occurrence data on the different BFRs under study received since the previous Opinions and by a certain deadline will be considered.

To guarantee an appropriate quality of the food data used in the exposure assessment, the initial dataset will be evaluated before being used to estimate dietary exposure. Among others, re-codification of samples under FoodEx classification will be carried out, as well as the application of the substitution method to left-censored data, the exclusion of suspect samples or those samples with incomplete information (e.g. absence of particular congeners). These steps will be carried out by the EFSA DATA Unit in collaboration with the members of the Working Group and/or Panel members.

Regarding the consumption levels of foods among the European population (**sub-question 12**), the EFSA Comprehensive European Food Consumption Database (Comprehensive Database) will be the source of the food consumption information. This database provides a compilation of existing national information on food consumption at individual level. It was first built in 2010 (EFSA, 2011a; Huybrechts et al., 2011; Merten et al., 2011) and updated frequently³. Details on how the Comprehensive Database is used were published in the Guidance of EFSA (EFSA, 2011a).

As indicated by the EFSA Working Group on Food Consumption and Exposure (EFSA, 2011b), dietary surveys with only one day per subject will only be considered for acute exposure as they are not adequate to assess repeated exposure. Similarly, subjects who participated only one day in the dietary studies, when the protocol prescribed more reporting days per individual, will also be excluded for the chronic exposure assessment.

To estimate the human dietary exposure (**sub-question 13**), both occurrence and consumption data will be codified and classified according to the FoodEx classification system (EFSA, 2011c). FoodEx is a food classification system developed by the former EFSA DCM Unit in 2009 with the objective of simplifying the linkage between occurrence and food consumption data when assessing the exposure to hazardous substances. It contains 20 main food groups (first level), which are further divided into subgroups having 140 items at the second level, 1,261 items at the third level and reaching about 1 800 end-points (food names or generic food names) at the fourth level. The EFSA Evidence

² <http://www.efsa.europa.eu/en/data/call/datex101217>

³ <http://www.efsa.europa.eu/en/datexfoodcdb/datexfooddb>

Management Unit will verify the correct application of FoodEx classification to the data before dietary exposure is estimated.

The CONTAM Panel considered that only chronic dietary exposure to BFRs is to be assessed for the general population. For this, food consumption and body weight data at the individual level will be accessed in the Comprehensive Database. Food occurrence data and consumption data will be linked at the least possible aggregated FoodEx level. In addition, the different food commodities will be grouped within each food category to better explain their contribution to the total dietary exposure to BFRs. Exposure estimates will be calculated per dietary survey and age class. The mean and the high (95th percentile) chronic dietary exposures will be calculated by combining BFRs mean occurrence values for food samples collected in different countries (pooled European occurrence data) with the average daily consumption for each food at individual level in each dietary survey. When occurrence data on BFRs are reported on fat content basis, consumption levels will be converted into amount of fat before dietary exposure is estimated. When the fat content of consumed foods is not available for specific eating occasions, an average value will be derived according to the different levels of hierarchy of the FoodEx1 catalogue from the available consumption data.

The estimates will be performed by the EFSA Evidence Management Unit. All analyses will be run using the SAS Statistical Software.

Sub-questions 11, 14 and 15 will be addressed narratively by carrying out a literature search to identify reviews as well as other peer-reviewed single studies published in the open literature that will be screened and evaluated by relevant domain experts from the Working Group.

A.4. Method to address the uncertainties in the risk assessment

The evaluation of the inherent uncertainties in the risk assessments on BFRs will be performed based on the guidance of the Opinion of the Scientific Committee related to Uncertainties in Dietary Exposure Assessment (EFSA, 2007), the report on 'Characterizing and Communicating Uncertainty in Exposure Assessment' (WHO/IPCS, 2008), the new guidance on uncertainties of the EFSA Scientific Committee (EFSA Scientific Committee, 2018) and the guidance on communication of uncertainty in scientific assessments (EFSA, 2019).

A.5. Approach for reaching risks characterisation conclusions

The general principles of the risk characterisation for chemicals in food as described by WHO/IPCS (2009) will be applied as well as the different EFSA guidance documents relevant to this step of the risk assessment (see Section A.1 above).

A.6. Plans for updating the literature searches and dealing with newly available evidence

The literature searches performed will be repeated approximately 7 and 4 months before the planned date of endorsement for public consultation and adoption of the Opinions. The scientific papers retrieved by these additional searches will be screened for relevance by the members of the Working Group and EFSA staff and included in the draft Opinions as appropriate by the Working Group experts.

A.7. Public consultation

In line with EFSA's policy on openness and transparency, and in order for EFSA to receive comments on its work from the scientific community and stakeholders, EFSA engages in public consultations on key issues. Accordingly, the draft Opinions on BFRs that will be developed will be released for open public consultation before their final adoption by the CONTAM Panel.

The comments received will be evaluated by the WG on BFRs in food and the CONTAM Panel and wherever appropriate taken into account for finalisation of the draft Opinion. An EFSA technical report on the outcome of the public consultation will be published together with the final Opinion, that will

include the comments as received from interested parties and the EFSA responses and explanations how the comments were considered for finalisation of the draft Opinion.

A.8. History of the amendments

The following amendments to the protocol were introduced before final adoption of the draft Opinion on the update of the risk assessment of HBCDDs in Food:

Introduction to Annex A: the recent draft framework for protocol development for EFSA's scientific assessments (EFSA, 2020) was mentioned and indicated that the current protocol for the BFRs risk assessment is in accordance with its principles.

A.2. Method for answering the sub-questions: Four EFSA guidances pertaining to risk assessment were added: (i) Scientific Opinion on the guidance on the use of the weight of evidence approach in scientific assessments (EFSA Scientific Committee, 2017b), (ii) Guidance on the assessment of the biological relevance of data in scientific assessments (EFSA Scientific Committee, 2017c). (iii) Guidance on Uncertainty Analysis in Scientific Assessments (EFSA Scientific Committee, 2018). (iv) Guidance on Communication of Uncertainty in Scientific Assessments (EFSA, 2019).

A.3. Method to address the exposure assessment sub-questions: it was clarified that the Comprehensive Database is updated continuously.

A.7. Public consultation: a new sub-section (A.7.) was added to acknowledge that all the draft updates of the risk assessments on BFRs will be subject to public consultation.

References

- EFSA (European Food Safety Authority), 2007. Guidance of the Scientific Committee on a request from EFSA related to Uncertainties in Dietary Exposure Assessment. EFSA Journal 2007;5(1):438, 54 pp. <https://doi.org/10.2903/j.efsa.2007.438>
- EFSA (European Food Safety Authority), 2009. Guidance of the Scientific Committee on transparency in the scientific aspects of risk assessments carried out by EFSA. Part 2: General principles. EFSA Journal 2009;7(6):1051, 22 pp. <https://doi.org/10.2903/j.efsa.2009.1051>
- EFSA (European Food Safety Authority), 2010a. Management of left-censored data in dietary exposure assessment of chemical substances. EFSA Journal 2010;8(3):1557, 96 pp. <https://doi.org/10.2903/j.efsa.2010.1557>
- EFSA (European Food Safety Authority), 2010b. Standard sample description for food and feed. EFSA 3232 Journal 2010, 8(1):1457, 54 pp. <https://doi.org/10.2903/j.efsa.2010.1457>
- EFSA (European Food Safety Authority), 2011a. Use of the EFSA Comprehensive European Food Consumption Database in Exposure Assessment. EFSA Journal 2011;9(3):2097, 34 pp. <https://doi.org/10.2903/j.efsa.2011.2097>
- EFSA (European Food Safety Authority), 2011b. Overview of the procedures currently used at EFSA for the assessment of dietary exposure to different chemical substances. EFSA Journal 2011;9(12):2490, 33 pp. <https://doi.org/10.2903/j.efsa.2011.2490>
- EFSA (European Food Safety Authority), 2011c. Evaluation of the FoodEx, the food classification system applied to the development of the EFSA Comprehensive European Food Consumption Database. EFSA Journal 2011;9(3):1970, 27 pp. <https://doi.org/10.2903/j.efsa.2011.1970>
- EFSA (European Food Safety Authority), Hart A, Maxim L, Siegrist M, Von Goetz N, da Cruz C, Merten C, Mosbach-Schulz O, Lahaniatis M, Smith A and Hardy A, 2019. Guidance on Communication of Uncertainty in Scientific Assessments. EFSA Journal 2019;17(1):5520, 73 pp. <https://doi.org/10.2903/j.efsa.2019.5520>
- EFSA (European Food Safety Authority), Martino L, Aiassa E, Halldórsson TI, Koutsoumanis PK; Naegeli H, Baert K, Baldinelli F, Devos Y, Lodi F, Lostia A, Manini P, Merten C, Messens W, Rizzi V, Tarazona J, Titz A, Vos S, 2020. Draft framework for protocol development for EFSA's scientific assessments. EFSA supporting publication 2020:EN-1843, 46 pp. <https://doi.org/10.2903/sp.efsa.2020.EN-1843>
- EFSA CONTAM Panel (EFSA Panel on Contaminants in the Food Chain), 2011a. Scientific Opinion on Hexabromocyclododecanes (HBCDDs) in Food. EFSA Journal 2011;9(7):2296, 118 pp. <https://doi.org/10.2903/j.efsa.2011.2296>

- EFSA CONTAM Panel (EFSA Panel on Contaminants in the Food Chain), 2011b. Scientific Opinion on Polybrominated Diphenyl ethers (PBDEs) in Food. EFSA Journal 2011;9(5):2156, 274 pp. <https://doi.org/10.2903/j.efsa.2011.2156>
- EFSA CONTAM Panel (EFSA Panel on Contaminants in the Food Chain), 2011c. Scientific Opinion on Tetrabromobisphenol A (TBBPA) in Food. EFSA Journal 2011;9(12):2477, 67 pp. <https://doi.org/10.2903/j.efsa.2011.2477>
- EFSA CONTAM Panel (EFSA Panel on Contaminants in the Food Chain), 2012a. Scientific Opinion on Brominated Flame Retardants (BFRs) in Food: Brominated Phenols and their Derivatives. EFSA Journal 2012;10(4):2634, 42 pp. <https://doi.org/10.2903/j.efsa.2012.2634>
- EFSA CONTAM Panel (EFSA Panel on Contaminants in the Food Chain), 2012b. Scientific Opinion on Emerging and Novel Brominated Flame Retardants (BFRs) in Food. EFSA Journal 2012;10(10):2908, 133 pp. <https://doi.org/10.2903/j.efsa.2012.2908>
- EFSA Scientific Committee, 2011. Scientific Opinion on genotoxicity testing strategies applicable to food and feed safety assessment. EFSA Journal 2011;9(9):2379, 69 pp. <https://doi.org/10.2903/j.efsa.2011.2379>
- EFSA Scientific Committee, 2012a. EFSA Scientific Committee; Guidance on selected default values to be used by the EFSA Scientific Committee, Scientific Panels and Units in the absence of actual measured data. EFSA Journal 2012;10(3):2579, 32 pp. <https://doi.org/10.2903/j.efsa.2012.2579>
- EFSA Scientific Committee, 2012b. Scientific Opinion on Risk Assessment Terminology. EFSA Journal 2012;10(5):2664, 43 pp. <https://doi.org/10.2903/j.efsa.2012.2664>
- EFSA Scientific Committee, Hardy A, Benford D, Halldorsson T, Jeger MJ, Knutsen KH, More S, Mortensen A, Naegeli H, Noteborn H, Ockleford C, Ricci A, Rychen G, Silano V, Solecki R, Turck D, Aerts M, Bodin L, Davis A, Edler L, Gundert-Remy U, Sand S, Slob W, Bottex B, Abrahantes JC, Marques DC, Kass G and Schlatter JR, 2017a. Update: Guidance on the use of the benchmark dose approach in risk assessment. EFSA Journal 2017;15(1):4658, 41 pp. <https://doi.org/10.2903/j.efsa.2017.4658>
- EFSA Scientific Committee, Hardy A, Benford D, Halldorsson T, Jeger MJ, Knutsen HK, More S, Naegeli H, Noteborn H, Ockleford C, Ricci A, Rychen G, Schlatter JR, Silano V, Solecki R, Turck D, Benfenati E, Chaudhry QM, Craig P, Frampton G, Greiner M, Hart A, Hogstrand C, Lambre C, Luttik R, Makowski D, Siani A, Wahlström H, Aguilera J, Dorne J-L, Fernandez Dumont A, Hempen M, Valtueña Martínez S, Martino L, Smeraldi C, Terron A, Georgiadis N and Younes M, 2017b. Scientific Opinion on the guidance on the use of the weight of evidence approach in scientific assessments. EFSA Journal 2017;15(8):4971, 69 pp. <https://doi.org/10.2903/j.efsa.2017.4971>
- EFSA Scientific Committee, Hardy A, Benford D, Halldorsson T, Jeger MJ, Knutsen HK, More S, Naegeli H, Noteborn H, Ockleford C, Ricci A, Rychen G, Schlatter JR, Silano V, Solecki R, Turck D, Younes M, Bresson J-L, Griffin J, Hougaard Benekou S, van Loveren H, Luttik R, Messean A, Penninks A, Ru G, Stegeman JA, van der Werf W, Westendorf J, Woutersen RA, Barizzzone F, Bottex B, Lanzoni A, Georgiadis N and Alexander J, 2017c. Guidance on the assessment of the biological relevance of data in scientific assessments. EFSA Journal 2017;15(8):4970, 73 pp. <https://doi.org/10.2903/j.efsa.2017.4970>
- EFSA Scientific Committee, Benford D, Halldorsson T, Jeger MJ, Knutsen HK, More S, Naegeli H, Noteborn H, Ockleford C, Ricci A, Rychen G, Schlatter JR, Silano V, Solecki R, Turck D, Younes M, Craig P, Hart A, Von Goetz N, Koutsoumanis K, Mortensen A, Ossendorp B, Martino L, Merten C, Mosbach-Schulz O and Hardy A, 2018. Guidance on Uncertainty Analysis in Scientific Assessments. EFSA Journal 2018;16(1):5123, 39 pp. <https://doi.org/10.2903/j.efsa.2018.5123>
- EFSA Scientific Committee, More SJ, Bampidis V, Benford D, Benekou SH, Bragard C, Halldorsson TI, Hernandez-Jerez AF, Koutsoumanis K, Naegeli H, Schlatter JR, Silano V, Nielsen SS, Schrenk D, Turck D, Younes M, Benfenati E, Castle L, Cedergreen N, Hardy A, Laskowski R, Leblanc JC, Kortenkamp A, Ragas A, Posthuma L, Svendsen C, Solecki R, Testai E, Dujardin B, Kass GEN, Manini P, Jeddi MZ, Dorne J-LCM and Hogstrand C, 2019. Guidance on harmonised methodologies for human health, animal health and ecological risk assessment of combined exposure to multiple chemicals. EFSA Journal 2019;17(3):5634, 77 pp. <https://doi.org/10.2903/j.efsa.2019.5634>
- WHO/IPCS (World Health Organization/International Programme on Chemical Safety), 2008. Uncertainty and data quality in exposure assessment. Available online: <http://www.who.int/iris/handle/10665/44017>
- WHO/IPCS (World Health Organization/International Programme on Chemical Safety), 2009. Principles and Methods for the Risk Assessment of Chemicals in Food, International Programme on Chemical Safety, Environmental Health Criteria 240. Chapter 6: Dietary Exposure Assessment of Chemicals in Food. Available online: <http://www.who.int/ipcs/food/principles/en/index1.html>